<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05009680</url>
  </required_header>
  <id_info>
    <org_study_id>GULLIVER-2</org_study_id>
    <nct_id>NCT05009680</nct_id>
  </id_info>
  <brief_title>A Single and Repeat Dose Trial in Participants With Hepatic Impairment</brief_title>
  <official_title>GULLIVER-2 - A Single (Open-label) and Repeat Dose (Randomised, Placebo-controlled) Trial to Assess the Safety, Tolerability and Pharmacokinetics of GB1211 in Participants With Hepatic Impairment (Child Pugh B &amp; C)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Galecto Biotech AB</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Comac Medical</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Galecto Biotech AB</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a a single (open-label) and repeat dose (randomised, placebo controlled) trial&#xD;
      to assess the safety, tolerability and pharmacokinetics of GB1211 (Gal-3 inhibitor) in&#xD;
      participants with hepatic impairment (Child Pugh B and Child Pugh C)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PART 1 A single dose, open-label safety and PK study of GB1211 administered to participants&#xD;
      with moderate hepatic impairment (Child Pugh B) and to matched healthy participants&#xD;
      (controls).&#xD;
&#xD;
      PART 2 A randomised, double-blind, placebo-controlled study in participants with moderate&#xD;
      hepatic impairment (Child Pugh B). GB1211 or placebo will be administered daily for 12 weeks.&#xD;
&#xD;
      PART 3 A single dose, open-label safety and PK study of GB1211 administered to participants&#xD;
      with severe hepatic impairment (Child Pugh C) and to healthy participants (controls).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 9, 2021</start_date>
  <completion_date type="Anticipated">September 10, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 18, 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Parts 1 &amp; 3 Open Label, Single Dose Part 2 Randomised to either GB1211 or Placebo</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>Parts 1 &amp; 3 - Open Label, Single Dose Part 2 - Double-blind. The blinding will be maintained throughout the study.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Parts 1 Safety and Tolerability of GB1211</measure>
    <time_frame>11 Days</time_frame>
    <description>Incidence and severity of adverse events as reported by investigators</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Parts 2 Safety and Tolerability of GB1211</measure>
    <time_frame>12 Weeks</time_frame>
    <description>Incidence and severity of adverse events as reported by investigators</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Parts 3 Safety and Tolerability of GB1211</measure>
    <time_frame>11 Days</time_frame>
    <description>Incidence and severity of adverse events as reported by investigators</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part 2 Collagen Production and Breakdown Biomarkers</measure>
    <time_frame>12 Weeks</time_frame>
    <description>Assessment of liver fibrosis using pro-C3, CK18 and PAI-1 Biomarkers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2 Changes on liver and spleen stiffness</measure>
    <time_frame>12 Weeks</time_frame>
    <description>Assessment of liver and spleen stiffness measured by vibration control transient elastography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2 Changes in Liver Functional Capacity</measure>
    <time_frame>12 Weeks</time_frame>
    <description>Assessment of Liver functional Capacity measured by 13C methacetin breath test</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">54</enrollment>
  <condition>Hepatic Impairment</condition>
  <arm_group>
    <arm_group_label>Part 1 GB1211, Single Dose (Child Pugh B)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GB1211 is a galectin-3 inhibitor an orally available small molecule anti-fibrotic. It is administered orally twice a day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1 GB1211 Healthy Matched Participants, Single Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GB1211 is a galectin-3 inhibitor an orally available small molecule anti-fibrotic. It is administered orally twice a day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 GB1211 Multiple Dose, Twice a day (Child Pugh B)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GB1211 is a galectin-3 inhibitor an orally available small molecule anti-fibrotic. It is administered orally twice a day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 Placebo, Twice a day (Child Pugh B)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo is administered twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1 GB1211, Single Dose (Child Pugh C)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 1 GB1211 Healthy Matched Participants, Single Dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 3 GB1211 Healthy Matched Participants, Single Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 1 GB1211 Healthy Matched Participants, Single Dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GB1211</intervention_name>
    <description>GB1211 is a galectin-3 inhibitor an orally available small molecule anti-fibrotic. It is administered orally twice a day</description>
    <arm_group_label>Part 1 GB1211 Healthy Matched Participants, Single Dose</arm_group_label>
    <arm_group_label>Part 1 GB1211, Single Dose (Child Pugh B)</arm_group_label>
    <arm_group_label>Part 1 GB1211, Single Dose (Child Pugh C)</arm_group_label>
    <arm_group_label>Part 2 GB1211 Multiple Dose, Twice a day (Child Pugh B)</arm_group_label>
    <arm_group_label>Part 3 GB1211 Healthy Matched Participants, Single Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo is administered orally twice a day</description>
    <arm_group_label>Part 2 Placebo, Twice a day (Child Pugh B)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Main Inclusion Criteria:&#xD;
&#xD;
          1. Males or females, of any race, ≥ 18 and ≤ 75 years of age at enrolment&#xD;
&#xD;
          2. Body mass index (BMI) of ≥ 18-40 kg/m2&#xD;
&#xD;
          3. Participants with hepatic impairment:&#xD;
&#xD;
               1. PART 1 and PART 2: Moderate hepatic impairment, as defined by the Child-Pugh&#xD;
                  score (Child-Pugh B) [1] who exhibit physical signs consistent with stable&#xD;
                  hepatic impairment and free of significant medical disorders unrelated to their&#xD;
                  hepatic disorder and are on stable concomitant medication for 2 weeks prior to&#xD;
                  and for the duration of this study&#xD;
&#xD;
               2. PART 3: Severe hepatic impairment as defined by the Child-Pugh score (Child Pugh&#xD;
                  C) who exhibit physical signs consistent with stable hepatic impairment and free&#xD;
                  of significant medical disorders unrelated to their hepatic disorder and are on&#xD;
                  stable concomitant medication for 2 weeks prior to and for the duration of this&#xD;
                  study&#xD;
&#xD;
          4. Healthy participants (controls) in PART 1 and PART 3:&#xD;
&#xD;
               1. Healthy as determined by the investigator, based on a medical evaluation&#xD;
                  including medical history, physical examination, laboratory tests and cardiac&#xD;
                  assessment&#xD;
&#xD;
               2. Match at least one of the participants with moderate or severe hepatic impairment&#xD;
                  with respect to gender, age (±10 years), and body mass index (BMI) ± 15% (ensure&#xD;
                  every participant with hepatic impairment has at least 1 matched control)&#xD;
&#xD;
          5. Women of non-childbearing potential defined as permanently sterile or postmenopausal&#xD;
&#xD;
          6. Males will agree to use contraception throughout the study and until 90-days after the&#xD;
             Follow-up visit&#xD;
&#xD;
          7. Male participants must agree to refrain from sperm donation from the date of&#xD;
             Randomisation (Day 1) until 90 days after the Follow up visit&#xD;
&#xD;
          8. Able to comprehend and willing to sign an ICF and to abide by the study restrictions&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        All parts and all groups (control healthy volunteers and hepatic impairment)&#xD;
&#xD;
          1. History of an organ transplant, including a remote history of bone marrow transplant&#xD;
&#xD;
          2. History of febrile illness within 7 days prior to the first dose of study drug or&#xD;
             participants with evidence of active infection&#xD;
&#xD;
          3. Use of any oral glucocorticoids at any dose within 30 days prior to Screening and&#xD;
             until study completion&#xD;
&#xD;
          4. Have previously completed or withdrawn from a study investigating GB1211 and have&#xD;
             previously received the investigational product&#xD;
&#xD;
          5. Participant who, in the opinion of the Investigator (or Designee), should not&#xD;
             participate in this study&#xD;
&#xD;
          6. Vulnerable/institutionalised patients&#xD;
&#xD;
          7. Patients related to Principal Investigator (PI)/site staff&#xD;
&#xD;
          8. If female, the participant is of child-bearing potential&#xD;
&#xD;
          9. Participation in a clinical study involving administration of an investigational agent&#xD;
             e.g. new chemical entity or a biological product in the past 90 days (or 5 multiples&#xD;
             of half-life, whichever is longer) prior to dosing.&#xD;
&#xD;
         10. Medical history of cardiac disease and/or clinically significant ECG abnormalities. An&#xD;
             abnormal ECG is defined as PR &gt; 220 msec, QRS complex &gt;120 msec, QTcF &gt; 450 msec&#xD;
             (males) and &gt; 470msec (females), or any other morphological changes, other than&#xD;
             nonspecific T-wave changes&#xD;
&#xD;
         11. Donation or loss of ≥ 400 mL blood or plasma less than 4 weeks prior to screening, or&#xD;
             longer if required by local regulations&#xD;
&#xD;
         12. Positive HIV test&#xD;
&#xD;
         13. Have received live vaccine(s) within 30 days prior to Screening or who will require a&#xD;
             vaccine(s) and until study completion&#xD;
&#xD;
         14. Use of any medications/products that may inhibit biliary excretion, e.g. bile salt&#xD;
             chelators, mycophenolic acid, warfarin, and digoxin, within 30 days prior to Screening&#xD;
             and until study completion&#xD;
&#xD;
         15. Use of any medications/products that may inhibit renal excretion; e.g. cimetidine,&#xD;
             pyrimethamine, dolutegravir, probenecid, within 30 days prior to Screening and until&#xD;
             study completion&#xD;
&#xD;
         16. Use of any medications/products that are known inhibitors of P-gp (e.g.&#xD;
             clarithromycin, fostamatinib, quinidine, quinine) and inducers of P-gp (e.g.&#xD;
             carbmazepine, rifampin, St. John's wort) within 30 days prior to Screening and until&#xD;
             study completion&#xD;
&#xD;
             Additional exclusion criteria for matched healthy control subjects:&#xD;
&#xD;
         17. Use of any prescription or non-prescription medication (OTC), herbal medication,&#xD;
             dietary supplements or vitamins during 30 days prior to dosing. Acetaminophen is&#xD;
             acceptable&#xD;
&#xD;
         18. History or presence of liver disease or liver injury as indicated by an abnormal liver&#xD;
             function profile such as AST, ALT, alkaline phosphatase, or serum bilirubin&#xD;
&#xD;
         19. A positive Hepatitis C test or a positive Hepatitis B surface antigen (HBsAg)&#xD;
&#xD;
         20. Estimated glomerular filtration rate (eGFR) &lt; 80 mL/[min*1.73 m²] (estimated using the&#xD;
             Modification of Diet in Renal Disease [MDRD] equation) at Screening&#xD;
&#xD;
             Additional exclusion criteria for hepatic impaired subjects:&#xD;
&#xD;
             Participants meeting any of the following exclusion criteria are not to be enrolled in&#xD;
             the study/randomised to treatment:&#xD;
&#xD;
         21. History of any known serious disease (such as cancer, except skin basal cell&#xD;
             carcinomas, major infection, clinically significant gastrointestinal disorder, major&#xD;
             autoimmune disease) or other disease which in the Investigator's opinion would exclude&#xD;
             the patient from the study&#xD;
&#xD;
         22. Estimated glomerular filtration rate (eGFR) &lt; 40 mL/[min*1.73 m²] (estimated using the&#xD;
             [MDRD] equation) at Screening&#xD;
&#xD;
         23. Use of any hepatotoxic drug (e.g. methotrexate, isoniazid, amiodarone) within 30 days&#xD;
             of Screening and until study completion&#xD;
&#xD;
         24. Use or intend to use any medications/products known to alter drug absorption,&#xD;
             metabolism, or elimination processes, including St. John's Wort, or other putatively&#xD;
             hepatoprotective herbal remedies such as milk thistle derivatives, within 30 days&#xD;
             prior to dosing, unless deemed acceptable by the Investigator (or Designee). Milk&#xD;
             thistle derivates or other hepatoprotective herbal remedies are allowed if stable dose&#xD;
             is administered 30 days before dosing&#xD;
&#xD;
         25. Use or intend to use slow release medications/products considered to still be active&#xD;
             within 14 days prior to Randomisation, unless deemed acceptable by the Investigator&#xD;
             (or Designee)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zahariy Krastev, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Comac Medical</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bertil Lindmark, MD</last_name>
    <phone>+4570705210</phone>
    <email>Clinicaltrials@galecto.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>COAMC Medical</name>
      <address>
        <city>Sofia</city>
        <zip>1000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zahariy Krastev, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Bulgaria</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 27, 2021</study_first_submitted>
  <study_first_submitted_qc>August 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 17, 2021</study_first_posted>
  <last_update_submitted>October 7, 2021</last_update_submitted>
  <last_update_submitted_qc>October 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Child Pugh B</keyword>
  <keyword>Child Pugh C</keyword>
  <keyword>Liver Cirrhosis</keyword>
  <keyword>Galectin 3 Inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

